Active surveillance for prostate cancer: is it too active?

BJU International

Volumn 118, Issue 3, 2016, Pages 343-

  Ehdaie, Behfar ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SURVEILLANCE; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER SCREENING; EDITORIAL; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INFECTION; INFECTION RISK; LOW RISK POPULATION; MALE; MEDICAL LITERATURE; MORBIDITY; PATIENT SAFETY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE NEEDLE BIOPSY; DISEASE EXACERBATION; HEALTH SURVEY; PROSTATE TUMOR; WATCHFUL WAITING;

PROSTATE SPECIFIC ANTIGEN;

DISEASE PROGRESSION; HUMANS; MALE; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84982107159     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13473     Document Type: Editorial

References (5)

1. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990–2013. JAMA 2015; 314: 80–2
2. Ehdaie B, Vertosick E, Spaliviero M et al. The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol 2014; 191: 660–4
3. Bokhorst LP, Lepistö I, Kakehi Y et al. Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study. BJU Int 2016; 118: 366–71
4. Tosoian JJ, Mamawala M, Epstein JI et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 2015; 33: 3379–85
5. Klotz L. Active surveillance: current and future directions. Curr Opin Urol 2013; 23: 237–8